A combined therapeutic regimen engineered by Moderna and Merck & Co. has demonstrated significant long-term clinical efficacy, reducing the risk of distant tumor metastasis by 59% after five years of follow-up, according to mid-stage trial data released on Thursday. The clinical protocol, which enrolled 157 melanoma patients between 2019 and 2021, evaluated whether combining Moderna’s experimental personalized vaccine, intismeran autogene, with Merck’s blockbuster immunotherapy Keytruda could successfully prevent cancer recurrence post-surgery.
The definitive five-year data survival matrix outlines several key performance metrics:
-
Overall Survival (OS) Rates: The cohort assigned to the combination treatment arm achieved an overall survival rate of 92.2%. Conversely, the control group treated exclusively with Keytruda monotherapy demonstrated an OS rate of 71.3%.
-
Recurrence and Mortality Risk: The integrated dual-action therapy reduced the net risk of disease recurrence or mortality by 49% at the five-year threshold, validating consistency with the intermediate three-year data published in 2023.
-
Safety and Tolerability Profile: The investigational vaccine’s safety metrics remained closely aligned with historical baseline analyses. Throughout the monitoring duration, seven fatalities were documented within each separate treatment arm, with the majority of instances driven directly by oncological progression.
The therapeutic mechanism behind intismeran autogene leverages a patient’s unique, tumor-specific genetic signature to program the native immune system to target and destroy malignant cells. Currently, a late-stage pivotal trial is actively ongoing to determine if this personalized vaccine sequence can establish a first-line standard of care when combined with Keytruda for melanoma patients. Additionally, parallel evaluations are underway in lung cancer and alternative tumor environments to assess the platform’s broader anti-recurrence capabilities. The consolidated clinical findings are scheduled for formal presentation at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago next week.